Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Aldoxorubicin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
    LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603328713/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Various Forms of Cancer
    CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Various Forms of Cancer

    21 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211221005233/en

    BUSINESSWIRE
    21 Dec 2021
    Share Share
    CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding
    CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding

    15 Jan 2021

    // NEWS

    https://in.news.yahoo.com/cytrx-highlights-aldoxorubicin-phase-2-130000215.html

    NEWS
    15 Jan 2021
    Share Share
    CytRx Highlights Use of Aldoxorubicin in Ph 2 Clinical Trials Yielding Positive
    CytRx Highlights Use of Aldoxorubicin in Ph 2 Clinical Trials Yielding Positive

    15 Jan 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210115005117/en

    BUSINESSWIRE
    15 Jan 2021
    Share Share
    CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Ph2 Study
    CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Ph2 Study

    12 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201013005364/en

    BUSINESSWIRE
    12 Oct 2020
    Share Share
    CytRx Corporation Highlights Significant +ve its Licensed Drug Aldoxorubicin
    CytRx Corporation Highlights Significant +ve its Licensed Drug Aldoxorubicin

    29 Jan 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cytrx-corporation-highlights-significant-positive-events-from-its-licensed-drug-aldoxorubicin-300995106.html

    PR NEWSWIRE
    29 Jan 2020
    Share Share